TrialEuropean journal of clinical pharmacology2017

Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects.

Poe-Hirr Hsyu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.